Intra-Cellular Ther Stock Target Price and Analyst Consensus

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

The current analyst and expert consensus on Intra-Cellular Ther is Buy, with 0 strong sell and 5 strong buy opinions. The current projected Intra-Cellular Ther target price consensus is 60.0 with 7 analyst opinions. The most common way Intra-Cellular Ther analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Intra-Cellular Ther executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Intra-Cellular Ther. We strongly encourage you to use your own analysis of Intra-Cellular Ther to validate this buy or sell advice. Intra-Cellular Ther buy-or-sell recommendation module provides average expert sentiment on the projected Intra-Cellular Ther target price to derive its highest and lowest estimates based on projected price volatility of 12.806. Please see Macroaxis Advice on Intra-Cellular Ther to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
  
Refresh
The current Gross Profit is estimated to increase to about 81.8 M, while Profit Margin is projected to decrease to (3.66) . Intra-Cellular Ther Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 22.64 Million. The current Investments is estimated to increase to about 334.8 M, while Accumulated Other Comprehensive Income is projected to decrease to (392.7 K).

Intra-Cellular Ther Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Intra-Cellular target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Intra-Cellular target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions7
Lowered Outlook0
Raized Outlook0
Buy
Most Intra-Cellular analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intra-Cellular stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intra-Cellular Ther, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Intra-Cellular Ther Target Price Projection

Intra-Cellular Ther's current and average target prices are 55.17 and 60.00, respectively. The current price of Intra-Cellular Ther is the price at which Intra-Cellular Ther is currently trading. On the other hand, Intra-Cellular Ther's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.

Current Price

Intra-Cellular Ther Market Quote on 4th of July 2022

Low Price53.13Odds
High Price57.12Odds

55.17

Target Price

Analyst Consensus On Intra-Cellular Ther Target Price

Low Estimate46.0Odds
High Estimate85.0Odds
Number of Analysts7
Standard Deviation12.806

60.0

Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Intra-Cellular Ther and the information provided on this page.

Intra-Cellular Ther Analyst Ratings

Intra-Cellular Ther's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Intra-Cellular Ther stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Intra-Cellular Ther's financials, market performance, and future outlook by experienced professionals. Intra-Cellular Ther's historical ratings below, therefore, can serve as a valuable tool for investors.

Analyst Consensus Breakdown

Average Consensus Estimates

About Intra-Cellular Ther Target Price Projections

Intra-Cellular Ther's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Intra-Cellular Ther and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Intra-Cellular depends on its intrinsic valuation, beta (i.e., risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Intra-Cellular Ther including analysis of its current option contracts.
Intra-Cellular Ther's latest option contracts expiring on 2022-07-15 are carrying combined implied volatility of 67.17 with a put-to-call open interest ratio of 1.85 over 26 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on 2022-07-15. The current put volume is at 126, with calls trading at the volume of 161. This yields a 0.78 put-to-call volume ratio. The Intra-Cellular Ther option chain provides detailed quote and price information for the current Intra-Cellular Ther option contracts. It shows all of Intra-Cellular Ther's listed puts, calls, expiration dates, strike prices, and other pricing information.

Open Interest Against 2022-07-15 Option Contracts

Intra-Cellular Ther option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Intra-Cellular Ther's lending market. For example, when Intra-Cellular Ther's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Intra-Cellular Ther, he or she must hedge the risk by shorting Intra-Cellular Ther stock over its option's life.
The chart above shows Intra-Cellular Ther's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Intra-Cellular Ther's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Intra-Cellular Ther's option, there is no secondary market available for investors to trade.

Intra-Cellular Ther Maximum Pain Price across 2022-07-15 Option Contracts

Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Intra-Cellular Ther close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Intra-Cellular Ther's stock options are financial instruments that give investors the right to buy or sell shares of Intra-Cellular Ther common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Intra-Cellular stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Intra-Cellular Ther's stock price goes up or down, the stock options follow.
Please see Macroaxis Advice on Intra-Cellular Ther to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Intra-Cellular Ther In The Money Call Balance

When Intra-Cellular Ther's strike price is surpassing the current stock price, the option contract against Intra-Cellular Ther stock is said to be in the money. When it comes to buying Intra-Cellular Ther's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' options written on Intra-Cellular Ther are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Intra-Cellular Current Options Market Mood

Intra-Cellular Ther's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Intra-Cellular Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of Intra-Cellular Ther's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Intra-Cellular Ther's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Intra-Cellular Ther's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.

Additional Intra-Cellular Ther Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Intra-Cellular Ther is a key component of Intra-Cellular Ther valuation and have some predictive power on the future returns of a Intra-Cellular Ther.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Intra-Cellular Ther's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Intra-Cellular Ther in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
51.0655.5059.94
Details
Intrinsic
Valuation
LowReal ValueHigh
52.9757.4161.85
Details
Naive
Forecast
LowNext ValueHigh
57.1461.5866.02
Details
Earnings
Estimates (5)
LowProjected EPSHigh
-3.53-3.46-3.32
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Intra-Cellular Ther. Your research has to be compared to or analyzed against Intra-Cellular Ther's peers to derive any actionable benefits. When done correctly, Intra-Cellular Ther's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Intra-Cellular Ther.

Additional Intra-Cellular Ther Value Projection Modules

Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Intra-Cellular Ther is a key component of Intra-Cellular Ther valuation and have some predictive power on the future returns of a Intra-Cellular Ther.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Intra-Cellular Ther's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Intra-Cellular Ther in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
51.0655.5059.94
Details
Intrinsic
Valuation
LowReal ValueHigh
52.9757.4161.85
Details
Naive
Forecast
LowNext ValueHigh
57.1461.5866.02
Details
Earnings
Estimates (5)
LowProjected EPSHigh
-3.53-3.46-3.32
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Intra-Cellular Ther. Your research has to be compared to or analyzed against Intra-Cellular Ther's peers to derive any actionable benefits. When done correctly, Intra-Cellular Ther's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Intra-Cellular Ther.

Trending Themes

If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
Healthcare
Invested less than 1 share
Macroaxis Index
Invested few shares
IT
Invested few shares
Investor Favorites
Invested less than 1 share
Please see Macroaxis Advice on Intra-Cellular Ther to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
The data published in Intra-Cellular Ther's official financial statements usually reflect Intra-Cellular Ther's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Intra-Cellular Ther. For example, before you start analyzing numbers published by Intra-Cellular accountants, it's critical to develop an understanding of what Intra-Cellular Ther's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Intra-Cellular Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intra-Cellular Ther's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Intra-Cellular Ther's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Intra-Cellular Ther. Please utilize our Beneish M Score to check the likelihood of Intra-Cellular Ther's management to manipulate its earnings.